当前位置: X-MOL 学术Mass Spectrom. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The next “sweet” spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection
Mass Spectrometry Reviews ( IF 6.6 ) Pub Date : 2021-11-12 , DOI: 10.1002/mas.21748
Yuanwei Xu 1, 2 , Yuefan Wang 1 , Naseruddin Höti 1 , David J Clark 1 , Shao-Yung Chen 1, 2 , Hui Zhang 1, 2
Affiliation  

Pancreatic ductal adenocarcinoma (PDAC) is the most common neoplastic disease of the pancreas, accounting for more than 90% of all pancreatic malignancies. As a highly lethal malignancy, PDAC is the fourth leading cause of cancer-related deaths worldwide with a 5-year overall survival of less than 8%. The efficacy and outcome of PDAC treatment largely depend on the stage of disease at the time of diagnosis. Surgical resection followed by adjuvant chemotherapy remains the only possibly curative therapy, yet 80%–90% of PDAC patients present with nonresectable PDAC stages at the time of clinical presentation. Despite our advancing knowledge of PDAC, the prognosis remains strikingly poor, which is primarily due to the difficulty of diagnosing PDAC at the early stages. Recent advances in glycoproteomics and glycomics based on mass spectrometry have shown that aberrations in protein glycosylation plays a critical role in carcinogenesis, tumor progression, metastasis, chemoresistance, and immuno-response of PDAC and other types of cancers. A growing interest has thus been placed upon protein glycosylation as a potential early detection biomarker for PDAC. We herein take stock of the advancements in the early detection of PDAC that were carried out with mass spectrometry, with special focus on protein glycosylation.

中文翻译:

胰腺导管腺癌的下一个“甜蜜”点:用于早期检测的糖蛋白

胰腺导管腺癌(PDAC)是胰腺最常见的肿瘤性疾病,占所有胰腺恶性肿瘤的90%以上。作为一种高致死率的恶性肿瘤,PDAC 是全球第四大癌症相关死亡原因,其 5 年总生存率低于 8%。PDAC 治疗的功效和结果很大程度上取决于诊断时的疾病阶段。手术切除后进行辅助化疗仍然是唯一可能的治愈疗法,但 80%–90% 的 PDAC 患者在临床表现时处于不可切除的 PDAC 分期。尽管我们对 PDAC 的了解不断深入,但其预后仍然非常差,这主要是由于早期诊断 PDAC 的困难。基于质谱的糖蛋白组学和糖组学的最新进展表明,蛋白质糖基化的畸变在 PDAC 和其他类型癌症的致癌、肿瘤进展、转移、化疗耐药和免疫反应中发挥着关键作用。因此,人们越来越关注蛋白质糖基化作为 PDAC 的潜在早期检测生物标志物。我们在此总结了利用质谱法进行 PDAC 早期检测的进展,特别关注蛋白质糖基化。
更新日期:2021-11-12
down
wechat
bug